Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash & Equivalents: 2012-2025

Historic Cash & Equivalents for Agios Pharmaceuticals (AGIO) over the last 14 years, with Sep 2025 value amounting to $92.7 million.

  • Agios Pharmaceuticals' Cash & Equivalents fell 63.46% to $92.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.7 million, marking a year-over-year decrease of 63.46%. This contributed to the annual value of $76.2 million for FY2024, which is 13.56% down from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Cash & Equivalents stood at $92.7 million, which was up 14.64% from $80.9 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Cash & Equivalents peaked at $1.9 billion during Q1 2021, and registered a low of $64.3 million during Q3 2023.
  • Over the past 3 years, Agios Pharmaceuticals' median Cash & Equivalents value was $84.8 million (recorded in 2023), while the average stood at $102.5 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Cash & Equivalents spiked by 2,019.16% in 2021, and later crashed by 95.76% in 2022.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' Cash & Equivalents stood at $203.1 million in 2021, then plummeted by 31.44% to $139.3 million in 2022, then crashed by 36.66% to $88.2 million in 2023, then fell by 13.56% to $76.2 million in 2024, then plummeted by 63.46% to $92.7 million in 2025.
  • Its last three reported values are $92.7 million in Q3 2025, $80.9 million for Q2 2025, and $79.0 million during Q1 2025.